13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q4 2023. See the latest, Q2 2026 →
Reported value
$3.94B
+0.5% on the quarter before
Positions
363
186 new · 258 sold out
Top 10
26.7%
of the value
Est. gain
+$71.4M
on stocks held all quarter
Est. return
+4.0%
on those stocks since Q3 2023
Positions as of Dec 31, 2023, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 49% of the reported value, each sized by its share, colored by what the fund did with it since Q3 2023. Striped tiles are options.
Largest buys
Since Q3 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Humana Inc~$102.6MAdded · 1.6% → 4.1%+224,041 shares
- Pioneer Nat Res Co~$79.7MAdded · 0.1% → 2.1%+354,238 shares
- Karuna Therapeutics Inc~$62.8MAdded · 0.0% → 1.6%+198,264 shares
- Westrock Co~$59.8MAdded · 0.6% → 2.2%+1,441,471 shares
- Sp Plus Corp~$52.5MNew · 0.0% → 1.3%+1,025,013 shares
- Olink Hldg Ab~$51.5MNew · 0.0% → 1.3%+2,049,051 shares
- Mirati Therapeutics Inc~$49.0MNew · 0.0% → 1.2%+834,390 shares
- Immunogen Inc~$48.3MNew · 0.0% → 1.2%+1,629,285 shares
- Novartis Ag~$44.5MAdded · 2.1% → 3.2%+440,244 shares
- The Cigna Group~$43.9MAdded · 0.3% → 1.5%+146,547 shares
Largest sells
Since Q3 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- New Relic Inc~$98.3MSold out · 2.5% → 0.0%−1,148,323 shares
- Baxter Intl Inc~$91.4MSold out · 2.3% → 0.0%−2,421,802 shares
- Abcam Plc~$80.5MSold out · 2.1% → 0.0%−3,559,341 shares
- Activision Blizzard Inc~$74.8MSold out · 1.9% → 0.0%−798,758 shares
- Seagen Inc~$74.1MSold out · 1.9% → 0.0%−349,204 shares
- Vmware Inc~$66.7MSold out · 1.7% → 0.0%−400,947 shares
- Medtronic Plc~$56.6MCut · 2.6% → 1.3%−686,678 shares
- Horizon Therapeutics Pub L~$52.5MSold out · 1.3% → 0.0%−453,622 shares
- National Instrs Corp~$50.4MSold out · 1.3% → 0.0%−845,732 shares
- Denbury Inc~$46.5MSold out · 1.2% → 0.0%−474,531 shares
Holdings
As of Dec 31, 2023. Changes are in shares against Sep 30, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Humana IncCOM · shares +178% · price −5.9% | 4.1% | $160.1M | −$3.6M | ||||||||
| Merck & Co IncCOM · shares +8.5% · price +5.9% | 3.9% | $152.2M | +$7.8M | ||||||||
| Novartis AgSPONSORED ADR · shares +55% · price −0.9% | 3.2% | $125.2M | −$711,731 | ||||||||
| Albertsons Cos IncCOMMON STOCK · shares −16% · price +1.1% | 2.3% | $90.5M | +$983,689 | ||||||||
| Abbott LabsCOM · shares −21% · price +13.6% | 2.3% | $90.0M | +$10.8M | ||||||||
| Zimmer Biomet Holdings IncCOM · shares −33% · price +8.4% | 2.3% | $89.8M | +$7.0M | ||||||||
| Westrock CoCOM · shares +214% · price +16.0% | 2.2% | $87.9M | +$3.9M | ||||||||
| Churchill Capital Corp ViiCOM CL A · shares 0% · price +0.5% | 2.2% | $87.2M | +$415,310 | ||||||||
| Elanco Animal Health IncCOM · shares −27% · price +32.6% | 2.2% | $86.2M | +$21.2M | ||||||||
| Encompass Health CorpCOM · shares +18% · price −0.7% | 2.1% | $83.2M | −$466,723 | ||||||||
| Pioneer Nat Res CoCOM · shares +2,238% · price −2.0% | 2.1% | $83.2M | −$73,931 | ||||||||
| Splunk IncCOM · shares +1.9% · price +4.2% | 2.1% | $83.2M | +$3.3M | ||||||||
| Pnm Res IncCOM · shares −4.9% · price −6.7% | 2.1% | $83.0M | −$6.0M | ||||||||
| Karuna Therapeutics IncCOM · shares +5,082% · price +87.2% | 1.6% | $64.0M | +$575,086 | ||||||||
| Mckesson CorpCOM · shares −0.8% · price +6.5% | 1.5% | $60.0M | +$3.6M | ||||||||
| Amedisys IncCOM · shares +1.8% · price +1.8% | 1.5% | $58.8M | +$1.0M | ||||||||
| The Cigna GroupCOM · shares +322% · price +4.7% | 1.5% | $57.5M | +$608,696 | ||||||||
| Capri Holdings LimitedSHS · shares −14% · price −4.5% | 1.4% | $56.6M | −$2.7M | ||||||||
| Cytokinetics IncNOTE 3.500% 7/0 · shares +11% · price +107.4% | 1.4% | $54.5M | — | ||||||||
| Sp Plus CorpCOM · shares New | 1.3% | $52.5M | — | ||||||||
| Gsk PlcSPONSORED ADR · shares −13% · price +2.2% | 1.3% | $52.2M | +$1.1M | ||||||||
| Medtronic PlcSHS · shares −52% · price +5.1% | 1.3% | $52.2M | +$2.5M | ||||||||
| Olink Hldg AbSPONSORED ADS · shares New | 1.3% | $51.5M | — | ||||||||
| Mirati Therapeutics IncCOM · shares New | 1.2% | $49.0M | — | ||||||||
| Immunogen IncCOM · shares New | 1.2% | $48.3M | — | ||||||||
| Total · 363 positions | 100% | $3.94B | +$71.4M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2023 to Q4 2023: 147 stocks held throughout, up $71.4M (+4.0%).
- Elanco Animal Health Inc+$21.2M+33%
- Abbott Labs+$10.8M+14%
- Merck & Co Inc+$7.8M+6%
- Zimmer Biomet Holdings Inc+$7.0M+8%
- Adma Biologics Inc+$5.5M+26%
- Brooge Energy Ltd−$3.0M−26%
- Humana Inc−$3.6M−6%
- Establishment Labs Hldgs Inc−$4.0M−47%
- Pnm Res Inc−$6.0M−7%
- Organon & Co−$6.5M−17%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |